SCHEMBL572569

SCHEMBL572569

NC(=O)N1CCN(C(N)=O)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HTR1A P08908 1/20 0.43
HTR2A P28223 1/20 0.43
HTR7 P34969 1/20 0.43
HTR6 P50406 1/20 0.43
POLB P06746 1/20 0.38
TDP1 Q9NUW8 3/20 0.36
CYP1A2 P05177 1/20 0.36
LMNA P02545 2/20 0.36
OR51E2 Q9H255 1/20 0.36
KMT2A Q03164 3/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
USP2 O75604 1/20 0.35
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
LTA4H P09960 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL422638 1.00
SCHEMBL14864006 0.87 GNAI3 (0.41) ALDH1A1HTTNPSR1HTR1AHTR2A
SCHEMBL21907248 0.87 GNAI3 (0.41) ALDH1A1HTTNPSR1HTR1AHTR2A
SCHEMBL6497217 0.87 ALDH1A1 (0.39) ALDH1A1HTTNPSR1HTR1AHTR2A
SCHEMBL31478000 0.87 ALDH1A1 (0.39) ALDH1A1HTTNPSR1HTR1AHTR2A
SCHEMBL957418 0.87 ALDH1A1 (0.39) ALDH1A1HTTNPSR1HTR1AHTR2A
SCHEMBL1363715 0.86
SCHEMBL788760 0.86
SCHEMBL302276 0.86
SCHEMBL3222967 0.85 CYP1A2 (0.59) ALDH1A1HTTNPSR1HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104069109-B Application of substituted piperazine-1, 4-diamide compound in pharmacy 中国医学科学院医药生物技术研究所 2017-01-25 CN claimed
CN-105902546-A Application of substituted piperazine-1,4-diamide compound in preparation of medicines for treating and/or preventing inflammation reaction 中国医学科学院医药生物技术研究所 2016-08-31 CN claimed
CN-105878247-A Application of substituted piperazine-1,4-diamide compound to preparation of medicines for treatment and/or prevention of senescence 中国医学科学院医药生物技术研究所 2016-08-24 CN claimed
CN-1228794-A Polyamide composition for removing polyphenol in liquid GRACE W R & CO (US) 1999-09-15 CN claimed
CN-105902546-B Application of the substituted piperazine -1,4- diamide compound in the medicine of preparation treatment and/or prevention of inflammation reaction 中国医学科学院医药生物技术研究所 2019-01-18 CN disclosed
CN-105902546-B Application of the substituted piperazine -1,4- diamide compound in the medicine of preparation treatment and/or prevention of inflammation reaction 中国医学科学院医药生物技术研究所 2019-01-18 CN disclosed
CN-105902546-B Application of the substituted piperazine -1,4- diamide compound in the medicine of preparation treatment and/or prevention of inflammation reaction 中国医学科学院医药生物技术研究所 2019-01-18 CN disclosed
CN-105878247-B Application of the substituted piperazine -1,4- diamide compound in preparation treatment and/or pre- anti-aging medicine 中国医学科学院医药生物技术研究所 2018-11-16 CN disclosed
CN-105878247-B Application of the substituted piperazine -1,4- diamide compound in preparation treatment and/or pre- anti-aging medicine 中国医学科学院医药生物技术研究所 2018-11-16 CN disclosed
CN-105878247-B Application of the substituted piperazine -1,4- diamide compound in preparation treatment and/or pre- anti-aging medicine 中国医学科学院医药生物技术研究所 2018-11-16 CN disclosed
EP-2975038-B1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES VIIV HEALTHCARE UK(NO 4) LTD (GB) 2017-07-12 EP disclosed
CN-104069109-B Application of substituted piperazine-1, 4-diamide compound in pharmacy 中国医学科学院医药生物技术研究所 2017-01-25 CN disclosed
US-20020119982-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2002-08-29 US disclosed
WO-2002062423-A1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-08-15 WO disclosed
US-20020061892-A1 Antiviral azaindole derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2002-05-23 US disclosed
EP-1140902-A1 TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS SCHERING CORPORATION (US) 2001-10-10 EP disclosed
EP-1140909-A1 NOVEL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE SCHERING CORPORATION (US) 2001-10-10 EP disclosed
WO-2001062255-A1 ANTIVIRAL AZAINDOLE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2001-08-30 WO disclosed
WO-2000039119-A1 NOVEL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE SCHERING CORPORATION (US) 2000-07-06 WO disclosed
WO-2000037459-A1 TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS SCHERING CORPORATION (US) 2000-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119982-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 ALDH1A1 1054/4885HTT 2003/4885NPSR1 2414/4885
US-20020061892-A1 Antiviral azaindole derivatives ZC3HAV1, MAVS, AZI2 ALDH1A1 1054/4885HTT 2003/4885NPSR1 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.